Related Links
ARALAST NP AATmosphere Program
Support for Alphas and families from the ARALAST NP AATmosphere program.
Alpha-1 as Seen
on PBS
Watch the PBS show about Alpha-1.
Patient Kits and Brochures
ARALAST NP Patient Education Kit
The updated ARALAST NP Patient Education Kit is a resource for your patients who are living with AAT deficiency*. Baxter is pleased to provide this helpful packet of information and resources, designed for Alpha-1 patients and their families.
*Also known as Alpha-1, alpha-1 antitrypsin deficiency, AATD, A1-PI deficiency, alpha-1 proteinase deficiency, A1AD, or hereditary or genetic emphysema
In the kit, your patient will find these booklets and tools:
- Take a Closer Look Booklet—Information about genetics, testing, diagnosis, augmentation therapy, and healthy living for AAT deficiency.
- ARALAST NP AATmosphere Program Booklet—This program surrounds patients and families with Alpha-1 support, including Insurance Assistance, One-on-One Support, Knowledge Network, and Alpha-1 Security.
- ARALAST NP AATmosphere Program Enrollment Form—Now it’s easy to start enjoying the benefits of this helpful program.
- Music for Relaxation CD—Your patients can relax with this selection of soothing woodwind arrangements.
You or your patients may order a Patient Education Kit online or by phone at 1-866-ARALAST (272-5278).
Take a Closer Look Patient Booklet
There is helpful information in this booklet for patients at every stage of the journey with AAT deficiency.
Topics include:
- Understanding AATD
- How AATD affects patients and families
- Genetics of AATD
- GINA and its protections
- Testing for AATD
- How to live better with AATD
- Augmentation therapy with ARALAST NP therapy
- Support programs from ARALAST NP AATmosphere program
- Glossary of Alpha-1 words
You may order the Patient Booklet online or by phone at 1-866-ARALAST (272-5278).
You may also download a copy of the booklet.
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
